

HMS ANTIMICROBIAL INITIATIVE TIER 1 TOOLKIT: QUICK REFERENCE GUIDE

This reference document provides a summary of the Tier 1 Toolkit for the HMS Antimicrobial Initiative that aims to implement global strategies to improve antimicrobial use

Convene a Workgroup to Focus on Tier 1 Strategies

The workgroup will likely be a new subgroup of your antimicrobial stewardship team. For maximum impact, the workgroup should consist of a multidisciplinary team that includes (but is not limited to) key stakeholders, such as a hospitalist, infectious disease physician and/or pharmacist, emergency medicine physician, house officers, IT personnel, microbiology lab representative, and nursing.

Tools and Resources:

- HMS site reports (hard copy distributed at collaborative wide meetings and live reports available daily via the HMS data entry system)
- CDC Core Elements of Hospital Antibiotic Stewardship Programs

Develop and Share Institutional Guidelines for UTI and Community-Acquired Pneumonia (CAP)

Develop institutional guidelines, locally-adapted from national and HMS guidelines, for treatment of community-acquired pneumonia (CAP) and UTI. If institution specific guidelines already exist, they should comply with the following:

CAP

Institutional guidelines should:

- Recommend 5-day antibiotic treatment duration for uncomplicated CAP
- Review the risk factors for Multi-Drug Resistant Organisms (MDRO) and/or Healthcare-Associated Pneumonia (HCAP)
- Provide recommendations for transition to oral therapy
- De-emphasize fluoroquinolones

UTI

Institutional guidelines should:

- Recommend against sending urine cultures in the absence of urinary symptoms
- Recommend against treating a positive urine culture in the absence of urinary symptoms
- De-emphasize fluoroquinolones
- Provide recommendations for transition to oral therapy

Tools and Resources:

- IDSA, HMS, and Institutional Guidelines:
 - CAP
 - UTI
- HMS Pocket Card Examples:
 - CAP
 - UTI

Integrate and Operationalize Institutional Guidelines for UTI and CAP

Integrate recommendations into key processes within the healthcare system such as into order sets, individual orders, discharge planning/processes, required yearly education for staff, etc.

Educate providers, including hospitalists, internal medicine, family medicine, emergency medicine physicians, residents, advanced practice professionals (APPs), and nursing staff about antibiotic resistance and appropriate antimicrobial prescribing.

Educate patients and families about antibiotic resistance and appropriate antimicrobial prescribing.

After 3 months of guideline use, obtain provider feedback from multiple groups (including hospitalists, internal medicine, emergency department, etc.), and modify accordingly.

Tools and Resources:

- CAP Order Set Example
- Patient Education Handout Example
 - Patients: What you need to know when you are prescribed an antibiotic



HMS ANTIMICROBIAL INITIATIVE TIER 1 TOOLKIT: QUICK REFERENCE GUIDE

Reduce Duration of Antibiotic Treatment for Uncomplicated CAP to 5 Days

Educate providers on the justification for 5 days of therapy for uncomplicated CAP

Evaluate and understand differences in provider groups (e.g., hospitalists, emergency medicine physicians). Target interventions to specific provider groups as necessary.

Encourage documentation of dose, indication and duration in the progress notes and on discharge.

Focus efforts on discharge prescribing, as HMS data shows that discharge prescriptions account for 80% of inappropriate antibiotic treatment for uncomplicated CAP.

Tools and Resources:

- Example of Email Feedback on Provider Performance for Duration of CAP Treatment
- Factsheet Emphasizing Focus on Discharge Prescriptions
- 72-hour Antibiotic Time Out Checklist
- Example of Hospital Newsletter Incorporating HMS Data
- CAP Pocket Card

Reduce Testing and Treatment of Asymptomatic Bacteriuria (ASB)

Educate providers, including hospitalists, internal medicine, family medicine, emergency medicine physicians, residents, advanced practice professionals (APPs), and nursing staff regarding the diagnosis of ASB vs UTI.

Utilize checklists to discourage requesting urine cultures if not indicated, in particular with frontline clinical staff.

Consider performing urine culture only when indicated, (example: reflex culture only with positive urinalysis).

Consider suppressing urine culture results by requiring providers to call the microbiology lab to request results (for non-catheterized patients).

Create a protocol assessing for UTI in patients whose primary symptom is altered mental status (AMS).

Tools and Resources:

- Educational Video: ASB vs UTI
- Checklist for Appropriate Urine Culture Ordering
- Inpatient Algorithm Assessing for UTI in Patients with Altered Mental Status
- (AMS)

De-escalate Antibiotic Treatment for UTI and Pneumonia

Utilize 72-hour Antibiotic Time Outs after starting antibiotics, including:

- Assess indication(s) for antibiotics
- Review culture results
- Adjust drug selection (de-escalate) and doses
- Consider switching to oral route
- Decide and document treatment duration

Encourage de-escalation of vancomycin for pneumonia with negative respiratory cultures and/or nasal swabs for MRSA.

Utilize HMS data to provide audit and feedback directly to providers regarding:

- Coverage of methicillin-resistant Staphylococcus aureus (MRSA) with negative MRSA nasal swabs and/or respiratory cultures
- Coverage of Pseudomonas with negative respiratory cultures

Utilize pharmacists to review cultures, and if positive, ensure that the narrowest, appropriate antibiotic coverage is chosen for the diagnosis.

Tools and Resources:

- Examples from Intermountain Health for Pharmacist-Driven Tools to Aid in De-escalation
- 72-hour Antibiotic Time Out Checklist
- HMS Site Reports (hard copy distributed at collaborative wide meetings and live reports available daily via the HMS data entry system)



Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.

Tier 1: Implement Global Strategies to Improve Antimicrobial Use

Convene a Workgroup to Focus on Tier 1 Strategies Convene a Workgroup to Focus on Tier 1 Strategies Convene a Workgroup Guidelines for Tract Infectio and Comm Acquired Pne (CAP)	ionalIntegrate andor UrinaryOperationalizeion (UTI)Institutionalnunity-Guidelines for UTI andeumoniaCAP	Reduce Duration of Antibiotic Treatment for Uncomplicated CAP to 5 Days	Reduce Testing and Treatment of Asymptomatic Bacteriuria (ASB)	De-escalate Antibiotic Treatment for UTI and Pneumonia
--	---	--	---	---



Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

TIER 1: GLOBAL STRATEGIES TO IMPROVE ANTIMICROBIAL USE				
Recommendation	Background, Rationale and Suggested Implementation Strategies	Resources, References & Tools		
1. Convene a Workgroup to Focus on Tier 1 Strategies	 The workgroup will likely be a new subgroup of your antimicrobial stewardship team. For maximum impact, the workgroup should consist of a multidisciplinary team that includes (but is not limited to) key stakeholders, such as a hospitalist, infectious disease physician and/or pharmacist, emergency medicine physician, house officers, IT personnel, microbiology lab representative, and nursing. Designate an internal lead for urinary tract infection (UTI) and pneumonia antibiotic-related quality improvement efforts. This person is responsible for ensuring implementation of interventions recommended by the workgroup, as well as identifying barriers and trouble-shooting during implementation. Meet quarterly to review data, define problem areas, identify underlying causes of problem areas and determine interventions for improvement. Communicate work to local leadership to ensure institutional buy-in. Engage key stakeholders in the design of interventions to encourage provider buy-in. When implementing interventions, consider using behavioral economic principles or social psychology to provide additional cultural incentives to change. Implement at least <u>two</u> new interventions as needed. 	 Resources & Tools: HMS site reports (hard copy distributed at collaborative wide meetings and live reports available daily via the HMS data entry system) CDC Core Elements of Hospital Antibiotic Stewardship Programs CDC Implementation of Antibiotic Stewardship Core Elements at Small and Critical Access Hospitals CDC Antibiotic Training Course Series 1 (Webinar-Free CE's available) CDC Antibiotic Training Course Series 2 (Webinar-Free CE's available) CDC Antibiotic Training Course Series 2 (Webinar-Free CE's available) IDSA Guidelines for Implementing an Antibiotic Stewardship Program Quality Improvement Organizations MITIGATE Antimicrobial Stewardship Toolkit: A practical guide for implementation in adult and pediatric emergency department and urgent care setting References: Saint S et al. Importance of leadership for successful implementation of interventions to prevent hospital-acquired infections. Infect Contol Hosp Epidemiol 2010. Strong leaders focus on overcoming barriers, inspire their employees, and think strategically while acting locally ANA/CDC White paper. Redefining the Antimicrobial Stewardship Team. 2017. Demonstrates importance of nursing and multidisciplinary antibiotic stewardship teams, highlighting roles individuals can play in stewardship efforts Heil E et al. Essential Role of Pharmacists in Antimicrobial Stewardship-trained pharmacists in a successful hospital stewardship-trained pharmacists in a successful hospital stewardship program. Sikkens JI et al. Behavioral Approach to Appropriate Antimicrobial Stewardship program. 		

		 Shared the problems of inappropriate prescribing, and allowed providers free choice to develop an intervention. Inappropriate antimicrobial prescribing decreased
2. Develop and Share Institutional Guidelines for UTI and CAP	 Develop institutional guidelines, locally-adapted from national and HMS guidelines, for treatment of community- acquired pneumonia (CAP) and urinary tract infection (UTI). If institution specific guidelines already exist, they should comply with the following: CAP Institutional guidelines should: Recommend 5-day antibiotic treatment duration for uncomplicated CAP Review the risk factors for multi-drug resistant organisms (MDRO) and/or Healthcare-Associated Pneumonia (HCAP) Provide recommendations for transition to oral therapy De-emphasize fluoroquinolones UTI Institutional guidelines should: Recommend against sending urine cultures in the absence of urinary symptoms Recommend against treating a positive urine culture in the absence of urinary symptoms De-emphasize fluoroquinolones Share the CAP and UTI guidelines with members of the work group and frontline providers to get feedback and to ensure buy-in. Publish guidelines in multiple formats, including booklet, hospital intranet, or an application for smartphones. 	Resources & Tools: Examples of Guidelines that could be locally-adapted to your institution: • National Guidelines: • Infectious Diseases Society of America (IDSA)/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. CID 2007. • IDSA Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. CID 2005. • IDSA and European Society for Microbiology and Infectious Disease Guidelines for Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women. CID 2010. • IDSA Guidelines for Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection (CA-UTI) in Adults. CID 2010. • HMS Guideline: • CAP • UTI • Institutional Guideline Examples (Appendix A) • UTI Guideline Examples (Appendix A) • UTI Guideline Examples (Appendix A) • UTI Guideline Examples (Appendix B) • Pocket Cards: • CAP (Appendix C) • UTI (Appendix D) • Example of Educational Computer Screensaver (Appendix E)

3. Integrate and	Educate providers, including hospitalists, internal	Resources & Tools:
Operationalize	medicine, family medicine, emergency medicine	Review HMS institution specific data to identify areas for local
		 Review HMS institution specific data to identify areas for local improvement <u>CAP Order Set Example</u> (Appendix F) <u>UTI Order Set Example</u> (Appendix G) <u>Patient Education Handout Example</u> Patients: What you need to know when you are prescribed an antibiotic (Appendix H) <u>References:</u> Meeker D et al. <u>Nudging guideline-concordant antibiotic prescribing: a randomized clinical trial.</u> JAMA Intern Med 2014. Displayed poster-sized commitment letters to avoid inappropriate antibiotic prescribing for Acute Respiratory Infections (ARIs) in exam rooms, providing patient/family education and behavioral "nudge" Hartley S et al. <u>Evaluating a Hospitalist-Based Intervention to Decrease Unnecessary Antimicrobial Use in Patients With Asymptomatic Bacteriuria</u>. Infect Contol Hosp Epidemiol 2016. Reduced treatment of ASB with educational sessions and pocket cards for hospitalists at all sites, and a pharmacistled review of positive urine cultures at one site Haas MK et al. <u>Effects of a Syndrome-Specific Antibiotic Stewardship Intervention for Inpatient Community-Acquired Pneumonia</u>. Open Forum Infect Dis 2016. Reduced duration of CAP treatment by development of institutional guidelines and integration into CPOE for treatment of non-ICU CAP using key stakeholders and hospitalist physician champions. For education/dissemination: utilized emails, posters in work rooms, presentations in Grand Rounds and division meetings
	 Involve hospitalist champions in the education and dissemination process. 	 Scymzcak J et al. <u>Pediatrician Perceptions of an Outpatient</u> <u>Antimicrobial Stewardship Intervention</u>. <i>Infect Contol Hosp</i> <i>Epidemiol</i> 2014. Qualitative study interviewing pediatricians after a stewardship intervention
		 Found skepticism of accuracy of audit and feedback reports.

4. Reduce Duration of	Educate providers on the justification for 5 days of	Resources & Tools:	
Antibiotic Treatment for	therapy for uncomplicated CAP	HMS Document: Treatment duration for uncomplicated	
Uncomplicated CAP to 5	Review CAP cases identified by HMS to implement high-	community-acquired pneumonia: the evidence in support of 5	
Days	yield interventions for recurrent problems	days.	
	• Evaluate and understand differences in provider groups (e.g., hospitalists, emergency medicine providers). Target interventions to specific provider groups as necessary.	 Review HMS site reports (hard copy distributed at collaborative wide meetings and live reports available daily via the HMS data entry system) for the following: Uncomplicated CAP treated with 5 days of antibiotics 	
	 Evaluate existing order sets to ensure antibiotic preferred options, doses, and durations are consistent with institutional pneumonia guidelines. 	 <u>Types of Reports Available via HMS Registry</u>: Hospital Specific, Provider Group Specific (i.e. hospitalist v. emergency room physician), or 	
	 Require documentation of dose and indication of antibiotics prescribed in the antibiotic order. 	Provider Specific HMS Guideline: 	
	 Encourage documentation of dose, indication, and duration of antibiotics in the progress note. 	 <u>CAP</u> <u>CAP Pocket Card (Appendix C)</u> Consider modifying to poster size for posting in 	
	 Require a 72-hour Antibiotic Time Out, during which total duration should be discussed. 	Factsheet Emphasizing Focus on Discharge Prescriptions	
	 Focus efforts on discharge prescribing, as HMS data shows that discharge prescriptions account for 80% of inappropriate antibiotic treatment for uncomplicated CAP. 	 (Appendix I) Educational Videos: Vaughn V. <u>Antibiotic Stewardship: Community-Acquired</u> <u>Pneumonia: for Providers</u> 	
	 Require documentation of the total duration of antibiotics in the discharge summary, potentially incorporating an area for antibiotic duration to be filled out in an automated discharge process. Incorporate nursing and pharmacy into review of the discharge antibiotic. 	 <u>72-hour Antibiotic Time Out Checklist</u> (Appendix J) <u>Example of hospital newsletter incorporating HMS data</u> (Appendix K) <u>Example of email feedback on provider performance for duration</u> 	
		of CAP treatment (Appendix L)	
	 Provide audit and feedback directly to providers regarding the duration of antibiotics they use for patients with uncomplicated CAP. 	References: • Avdic E et al. Impact of an Antimicrobial Stewardship Intervention on Shortening the Duration of Therapy for Community-acquired Pneumonia. Clin Infect Dis 2012.	
	 Consider incorporating compliance with treatment duration for uncomplicated CAP as part of hospitalists' performance targets (for compensation). 	 Reduced treatment duration of CAP with educational lectures based on survey results, and post-prescription pharmacy review with verbal feedback 	
		Yogo N et al. Intervention to Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital Discharge: A Novel Stewardship Approach. Infect Contol Hosp Epidemiol 2014	
		 Reduced antibiotic duration prescribed at discharge by developing a guideline for antibiotic selection and 	

		 treatment duration and performing pharmacy audit and feedback of discharge prescriptions Foolad F et al. <u>A multicenter stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community acquired pneumonia</u>. <i>J Antimicrob Chemother</i> 2018 Treatment duration for CAP was reduced by updating institutional CAP guidelines, providing educational sessions, and performing daily audit and feedback on appropriate treatment duration for CAP patients
5. Reduce Testing and	Educate providers, including hospitalists, internal	Resources & Tools:
Treatment of	medicine, family medicine, emergency medicine	Review HMS site reports (hard copy distributed at collaborative
Asymptomatic Bacteriuria (ASB)	physicians, residents, advanced practice professionals (APPs), and nursing staff regarding the diagnosis of ASB vs UTI.	 wide meetings and live reports available daily via the HMS data entry system) for the following: Testing of Asymptomatic Bacteriuria
	 Educate patients and family members regarding the diagnosis of ASB vs UTI. 	 Treatment of Asymptomatic Bacteriuria with Antibiotics <u>Types of Reports Available via HMS Registry</u>: Hospital Specific, Provider Group Specific (i.e.
	 Review ASB cases identified by HMS to direct high-yield intervention for recurrent problems. 	hospital specific, Provider Group specific (i.e. hospitalist v. emergency room physician), or Provider Specific
	 Evaluate and understand differences in provider groups (e.g., hospitalists, emergency department physicians). Target interventions to specific provider groups as necessary. 	 HMS Guideline: <u>UTI</u> <u>UTI Pocket Card</u> (Appendix D) Consider modifying to poster size for posting in
	 Evaluate existing order sets to ensure preferred antibiotic options, doses, and durations are consistent with institutional UTI guidelines (including pre-operative order sets, ED admission sets, "commonly ordered test" lists). 	workrooms Educational Videos: <u>ASB vs UTI</u> Trautner, B. <u>Antibiotic Stewardship: Urinary Tract</u>
	 Utilize clinical decision support tools to discourage inappropriate urine culture testing, by requiring documentation of symptom(s) as indication for the test. 	 <u>Infection: for Providers</u> <u>Checklist for Appropriate Urine Culture Ordering</u> (Appendix M) Tools for assessing a Urinary Tract Infection (UTI) in patients with Altered Mental Status (AMS)
	 Utilize checklists to discourage ordering of urine cultures by frontline clinical care team. 	 Inpatient Algorithm Assessing for UTI in Elderly Patients with AMS (Appendix N)
	 Require documentation of dose and indication of antibiotics prescribed in the antibiotic order. Consider adding documentation of urinary symptom necessitating treatment. 	 Mody, L. et al. <u>Urinary Tract Infections in Older Women: A</u> <u>Clinical Review</u>. JAMA 2014 <u>Example of hospital newsletter incorporating HMS data</u> (Appendix K)
	 Encourage documentation of dose, indication, and duration of antibiotics in the progress note. 	References:

 Encourage documentation of the total duration of antibiotics in discharge summary, potentially incorporating an area for antibiotic duration to be filled out in an automated discharge process. Provide audit and feedback directly to individual providers regarding their rates of testing and treatment for ASB. Consider performing urine cultures only when indicated, (example: reflex culture only with positive urinalysis). Consider suppressing urine culture results by requiring providers to call the microbiology lab to request results (for non-catheterized patients). Create a protocol assessing for UTI in patients whose primary symptom is altered mental status (AMS). 	 Leis JA et al. <u>Reducing Antimicrobial Therapy for Asymptomatic Bacteriuria Among noncatheterized inpatients: a proof of concept study.</u> <i>Clin Infect Dis</i> 2014. Intervention at the stage of lab reporting that withheld urine culture results of non-catheterized inpatients unless requested by a physician Jones CW et al. <u>Reflect urine culture cancellation in the emergency department</u>. <i>J Emerg Med</i> 2014. In the ED, authors estimate a 40% reduction in urine cultures if a culture was cancelled when urinalysis did not meet criteria (one of the following: white blood cell >10, + leukocyte esterase, + nitrites, + bacteria) Stagg A et al. <u>Impact of two-step urine culture ordering in the emergency department: a time series analysis</u>. <i>BMJ Qual Saf</i> 2017. In the ED, urine samples collected by nurses, then saved for 48 hours, and not processed without additional physician order Resulted in a decrease of urine cultures processed, decreased need for patient callbacks for positive cultures, and decrease in antibiotics prescribed for a urinary indication for those admitted Munigala et al. <u>Impact of order set design on urine culturing practices at an academic medical center emergency department</u>. <i>BMJ Qual Saf</i> 2017. Removing all urine culture orders except "urinalysis with reflex to microscopy" from frequently ordered list of tests for the ED resulting in decreasing daily urine culture rate by about half Trautner B et al. <u>Effectiveness of an Antimicrobial Stewardship Approach for Urinary Catheter-Associated Asymptomatic Bacteriuria</u>. <i>JAMA</i> 2015. A multifaceted educational implementation strategy in the VA to reduce urine culture ordering and inappropriate antibiotic prescribing in catheterized patients

6. De-escalate Antibiotic		 Schulz L et al. <u>Top Ten Myths Regarding the Diagnosis and</u> <u>Treatment of Urinary Tract Infections</u>. <i>J Emerg Med</i> 2016. Review of the evidence regarding commonly held misbeliefs surrounding urinary tract infections Vaughn V et al. <u>Revisiting the panculture</u>. <i>BMJ Qual Saf</i> 2016 Pan culturing for fever is costly and contributes to unnecessary cultures and inappropriate antibiotic use <u>Resources & Tools:</u>
Treatment for UTI and Pneumonia	 Require documentation of dose and indication of antibiotics prescribed in the antibiotic order. Encourage documentation of dose, indication, and duration of antibiotics in the progress note. Utilize 72-hour antibiotic time outs after starting antibiotics, including: Assess indication(s) for antibiotics Review culture results Adjust drug selection (de-escalate) and doses Consider switching to oral route Decide and document treatment duration Utilize pharmacists to review cultures, and if positive, ensure that the narrowest, appropriate antibiotic coverage is chosen for the diagnosis. Utilize HMS data to provide audit and feedback directly to providers regarding: Coverage of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) with negative MRSA nasal swabs and/or respiratory cultures Coverage de-escalation of vancomycin for pneumonia with negative respiratory cultures and/or nasal swabs for MRSA. Incorporate the effective duration of therapy into deescalation protocols (count all days of active therapy including IV). When reporting microbiology lab results consider: 	 Review HMS site reports (hard copy distributed at collaborative wide meetings and live reports available daily via the HMS data entry system) for the following Antibiotic treatment regimens for UTI and CAP/HCAP Discharge antibiotics Patients with negative culture for MRSA and on MRSA coverage Patients with negative culture for <i>Pseudomonas</i> and on pseudomonas coverage Examples from Intermountain Health for Pharmacist-driven tools to aid in de-escalation <u>De-escalation quick reference guide for pharmacists</u> (Appendix O) Antibiotic Time Out Checklist (Appendix J) References: Chotiprasitsakul D et al. <u>The Role of Negative Methicillin-Resistant Staphylococcus aureus Nasal Surveillance Swabs in Predicting the Need for Empiric Vancomycin Therapy. Open Forum Infect Dis 2017.</u> Among 11,441 ICU patients, a negative nasal MRSA surveillance swab had an NPV of 99.4% Labelle AJ et al. <u>A comparison of culture-positive and culture-negative health-care-associated pneumonia</u>. <i>Chest</i> 2010. For ICU and non-ICU HCAP patients, those that had a negative culture had lower severity of illness, hospital mortality, and hospital length of stay compared with those with a positive culture Buckel WR et al. <u>Broad-versus Narrow-Spectrum Oral Antibiotic Transition and Outcomes in Health Care-associated Pneumonia</u>. <i>Ann Am Throrac Soc</i> 2017.

 Providing recommendations on likely contaminants (e.g., ≥ 3 organisms in a urine culture) Selective reporting of antibiotic susceptibility results: (i.e. suppressing broad spectrum antibiotic susceptibility results when a narrow spectrum antibiotic is effective) 	 Retrospective review of patients admitted with HCAP and negative culture, initially treated with broad-spectrum antibiotics (anti-MRSA and/or anti-<i>Pseudomonas</i> activity) There was no increased 30-day readmission or all-cause mortality in patients transitioned to narrow spectrum compared to broad spectrum oral antibiotics. The majority of narrow spectrum antibiotics were oral beta-lactams Parente D et al. The Clinical Utility of Methicillin Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis with Antimicrobial Stewardship Implications. Clin Infect Dis 2018. A meta-analysis including 22 studies evaluating the diagnostic value of MRSA nasal screening in MRSA pneumonia. The negative predictive value (NPV) for CAP and HCAP was 98.1%. Musgrove MA et al Microbiology Comment Nudge Improves Pneumonia Prescribing Open Forum Infect Dis 2018. Changing report result for respiratory cultures with no dominant organism growth from "commensal respiratory flora" to "commensal respiratory flora only: No S. aureus/MRSA [methicillin-resistant Staphylococcus aureus] or P. [Pseudomonas] aeruginosa" resulted in increased de-escalation/discontinuation (39% vs 73%, P < .001) and was associated with a 5.5-fold increased odds of de-escalation.
---	---

This toolkit is a live document and will continually be updated as new tools are developed. Please visit the HMS website for the most up-to-date toolkit. If you have tools to be added to the toolkit, please see the HMS contact information below.

Contact Information:


Email: hospmedqi@umich.edu Website: <u>http://mi-hms.org/</u>



Appendix A

Michigan Medicine Pneumonia Guideline Treatment Pathway for Adult Patients with Pneumonia

The purpose of this document is to guide the appropriate treatment of adult patients presenting with pneumonia. Two pathways with different empiric treatment regimens based on risk of infection with multidrug-resistant (MDR) pathogens (including MRSA, *Pseudomonas* spp., *Acinetobacter* spp., organisms not susceptible to beta-lactams (ceftriaxone or ampicillin-sulbactam) and/or fluoroquinolones (ciprofloxacin, levofloxacin)) are shown below. Of note, since the 2005 American Thoracic Society/Infectious Diseases Society of America guidelines first introduced recommendations for healthcare associated pneumonia (HCAP), several studies have been published that question the predictive value of HCAP criteria for patients infected with drug-resistant pneumonia. Multiple studies have reported various risk factors and proposed scoring tools but methodology varies widely and thus an optimal model has not yet been identified. **Treatment recommendations below are based on disease severity and presence of additional risk factors for MDR pathogens. This will replace the previously defined HCAP criteria.**



	Pathway A (Part I)				
Indication	Common Pathogens	Empiric Therapy	Duration of Therapy	ys of therapy for pomplicated CAP ents	Comments
treatmen includes • Ampici PLUS A Clarithro Doxycyc • Ceftria: Cefotaxi: Azithron Clarithro Doxycyc <u>Alternative</u> <u>Non-Prefer</u> for patients cephalospo allergy to b macrolides	illin-Sulbactam izithromycin, or iline xone or me PLUS mycin, or eline <u>but HMS</u> <u>trred</u> treatment s with prin allergy, poth s and me/tetracycline,	Ist line: Ampicillin/sulbactam 3gm IV q6 hr (except if alcoholism with aspiration) PLUS Azithromycin 500mg IV/PO x 1 day, then 250mg q24 hr x 4 days PCN allergy without anaphylaxis, angioedema, or urticaria, or alcoholism with aspiratiom: Ceftriaxone 1gm IV q24 hr PLUS Azithromycin 500mg IV/PO x 1 day, then 250mg q24 hr x 4 days Consider the addition of anaerobic coverage with metronidazole 500mg PO q8 hr if aspiration with risk of enteric GNR ⁺ , empyema, lung abscess, or cavitary lesion Severe PCN and cephalosporin allergy (anaphylaxis, angioedema, hives): Levofloxacin 750mg IV/PO q24 hr Consider the addition of anaerobic coverage with metronidazole 500mg PO q8 hr if alcoholism with aspiration or aspiration with risk of entery (anaphylaxis, angioedema, hives): Levofloxacin 750mg IV/PO q24 hr Consider the addition of anaerobic coverage with metronidazole 500mg PO q8 hr if alcoholism with aspiration or aspiration with risk of empyema, lung abscess, or cavitary lesion Addition of vancomvcin Consider if high clinical suspicion for CA-MRSA (history of MRSA pneumonia or post-influenza pneumonia)	 Uncomplicated Pneumonia: 5 days for patients who defervesce within 72 hours and have no more than 1 sign of CAP instability at the time of antibiotic discontinuation⁺ Patients with delayed response should discontinue therapy 48-72 hours after defervesce and have no more than 1 sign of CAP instability⁺ at time antibiotic discontinuation. Pneumonia with nonfermenting GNRs (e.g. Pseudomonas, Achromobacter, Acinetobacter, Stenotrophomonas) should receive 7 days of therapy Complicated Pneumonia: Treat <i>Staph. aureus</i> for a minimum duration of 7 days Patients with empyema, infected pleural effusions, and bacteremia secondary to pneumonia may require longer durations of therapy. Bacteremic pneumococcal pneumonia should be treated for a minimum of 10-14 days. ID consult is recommended for patients with bacteremia. +CAP clinical signs of instability (if different than patient baseline status) HR ≥ 100 bpm RR ≥ 24 breaths/min SBP ≤ 90 mmHg Arterial O₂ sat ≤ 90% or pO₂ ≤ 60 mmHg on room air 	 Appropriately respiratory cult respiratory cult For culture neg oral therapy where clinical improvises and the stable for 48 here. 1st line: A BID plus course of PCN allera angioeder 200 mg Pt (complete) Severe PC not tolera Levofloxa Adjust levoflox for renal dysful levofloxacin lo Use azithromy 	ative pneumonia, transition to hen patient is afebrile with ement and hemodynamically ours: moxicillin/clavulanate 875 mg azithromycin (complete 5-day azithromycin) rgic, without anaphylaxis, ma, or urticaria: Cefpodoxime O BID plus azithromycin 5-day course of azithromycin) CN allergic patients who do ate cephalosporins: acin 750 mg PO q24 tacin and ampicillin/sulbactam netion. Always give ading dose of 750mg x 1 dose rcin 500 mg q24 hr if high ion for Legionella

	Pathway A (Part I)				
Indication	Common Pathogens	Empiric Therapy	Duration of Therapy	Comments	
Inpatient community -acquired pneumonia (Non-ICU patient)	Streptococcus pneumonia Haemophilus influenzae Moraxella catarrhalis Mycoplasma pneumoniae Legionella species	 1st line: Ampicillin/sulbactam 3gm IV q6 hr (except if alcoholism with aspiration) PLUS Azithromycin 500mg IV/PO x 1 day, then 250mg q24 hr x 4 days PCN allergy without anaphylaxis, angioedema, or urticaria, or alcoholism with aspiration: Ceftriaxone 1gm IV q24 hr PLUS Azithromycin 500mg IV/PO x 1 day, then 250mg q24 hr x 4 days Consider the addition of anaerobic coverage with metronidazole 500mg PO q8 hr if aspiration with risk of enteric GNR^T, empyema, lung abscess, or cavitary lesion Severe PCN and cephalosporin allergy (anaphylaxis, angioedema, hives): Levofloxacin 750mg IV/PO q24 hr Consider the addition of anaerobic coverage with metronidazole 500mg PO q8 hr if alcoholism with aspiration or aspiration with risk of empyema, lung abscess, or cavitary lesion Addition of vancomycin Consider if high clinical suspicion for CA-MRSA (history of MRSA pneumonia or post-influenza pneumonia) 	 Uncomplicated Pneumonia: 5 days for patients who defervesce within 72 hours and have no more than 1 sign of CAP instability at the time of antibiotic discontinuation[†] Patients with delayed response should discontinue therapy 48-72 hours after defervesce and have no more than 1 sign of CAP instability[†] at time antibiotic discontinuation. Pneumonia with nonfermenting GNRs (e.g. Pseudomonas, Achromobacter, Acinetobacter, Stenotrophomonas) should receive 7 days of therapy Complicated Pneumonia: Treat Staph. aureus for a minimum duration of 7 days Patients with empyema, infected pleural effusions, and bacteremia secondary to pneumonia may require longer durations of therapy. Bacteremic pneumococcal pneumonia should be treated for a minimum of 10-14 days. ID consult is recommended for patients with bacteremia. ⁺CAP clinical signs of instability (if different than patient baseline status) HR ≥ 100 bpm RR ≥ 24 breaths/min SBP ≤ 90 mmHg Arterial O₂ sat ≤ 90% or pO2 ≤ 60 mmHg on room air 	 Appropriately tailor therapy based on respiratory culture results. For culture negative pneumonia, transition to oral therapy when patient is afebrile with clinical improvement and hemodynamically stable for 48 hours: Ist line: Amoxicillin/clavulanate 875 mg BID plus azithromycin (complete 5-day course of azithromycin) PCN allergic, without anaphylaxis, angioedema, or urticaria: Cefpodoxime 200 mg PO BID plus azithromycin (complete 5-day course of azithromycin) Severe PCN allergic patients who do not tolerate cephalosporins: Levofloxacin 750 mg PO q24 Adjust levofloxacin and ampicillin/sulbactam for renal dysfunction. Always give levofloxacin loading dose of 750mg x 1 dose Use azithromycin 500 mg q24 hr if high clinical suspicion for Legionella 	



A Member of Trinity Health	IUS Innationt Cuid	ling for the Empiric	Treatment of Pneumonia
Infection	Antimicrobial Therapy [§]	Duration 5 days o	Comments if therapy for licated CAP
Community- acquired pneumonia (CAP) ¹ Non-ICU	Ceftriaxone 1g IV Q24h PLUS Azithromycin 500 mg IV/PO X1, then 250mg PO Q24h X 4 days OR doxycycline 100mg IV/PO Q12h (if macrolide intolerance/allergy)	5 days* *Longer durations of therapy may be indicated, depending upon clinical response 5 days if afebrile with <2 signs of clinical instability on	 bxacin is restricted to patients with a ented TypeI IgE-medicated penicillin or cephalosporin allergy (anaphylaxis) or any legitimate cephalosporin allergy or as PO therapy in patients tolerating PO Consider increased ceftriaxone dose of 2 grama Q24h if patient greater than 100kg
HMS Preferred empiric treatment for CAP includes • Ampicillin-Sulbactam PLUS Azithromycin, or Doxycycline • Ceftriaxone or Cefotaxime PLUS Azithromycin, or Doxycycline	Patients with a documented TypeI IgE- medicated penicillin or cephalosporin allergy OR any legitimate cephalosporin allergy OR as PO therapy in patients tolerating PO: Levofloxacin 750 mg ¹	days 3-5 Signs of Clinical Instability: • Arterial O2 sat \leq 90% • HR \geq 100 bpm • RR \geq 24 breaths/min • BP \leq 90 mmHg • Altered mental status (different than baseline)	 Consider doxycycline as an alternative to azithromycin in patients at high risk for QT prolongation Existing QT prolongation Hypokalemia Hypomagnesemia Significant bradycardia Bradyarrhythmias Uncompensated heart failure Patients receiving class IA or class II antiarrhythmic drugs Patients should be switched from IV to PO
Alternative but HMS <u>Non-Preferred</u> treatment for patients with cephalosporin allergy, allergy to both macrolides and doxycycline/tetracycline, or severe penicillin allergy	IV/PO Q24h	Signs of clinical instability impacting determination for therapy duration	 Future is should be switched from 17 to 10 when they are hemodynamically stable, improving clinically, and able to tolerate PO medications. Total duration (IV plus PO step down) described in previous column Options for oral step down therapy should target isolated pathogen. Options for PO step-down if no pathogen identified on respiratory culture: Amoxicillin/clavulanate 875mg Q12h PLUS/MINUS azithromycin Amoxicillin 1g Q8h¹ PLUS/MINUS azithromycin Cefpodoxime 200mg Q12h¹

- PLUS/MINUS azithromycin Cefuroxime 500mg Q12h¹ PLUS/MINUS azithromycin 0
- If TypeI IgE-mediated penicillin or any legitimate cephalosporin allergy: Levofloxacin 750mg Q24h¹ 0

§ Prior to confirmation of pathogen1. Refer to SJMHS antibiotic dosing tables for dose adjustments in renal dysfunction.



Infection	Antimicrobial	Duration	Comments
meetion	Therapy [§]	Durunon	Comments
Community- acquired pneumonia (CAP) ¹ Non-ICU	Ceftriaxone 1g IV Q24h PLUS Azithromycin 500 mg IV/PO X1, then 250mg PO Q24h X 4 days OR doxycycline 100mg IV/PO Q12h (if macrolide intolerance/allergy) Patients with a documented TypeI IgE- medicated penicillin or cephalosporin allergy OR any legitimate cephalosporin allergy OR as PO therapy in patients tolerating PO: Levofloxacin 750 mg ¹ IV/PO Q24h	 5 days* *Longer durations of therapy may be indicated, depending upon clinical response 5 days if afebrile with <2 signs of clinical instability on days 3-5 Signs of Clinical Instability: Arterial O2 sat ≤ 90% HR ≥ 100 bpm RR ≥ 24 breaths/min BP ≤ 90 mmHg Altered mental status (different than baseline) 	 Levofloxacin is restricted to patients with a documented TypeI IgE-medicated penicillin or cephalosporin allergy (anaphylaxis) or any legitimate cephalosporin allergy or as PO therapy in patients tolerating PO Consider increased ceftriaxone dose of 2 gram Q24h if patient greater than 100kg Consider doxycycline as an alternative to azithromycin in patients at high risk for QT prolongation Existing QT prolongation Hypokalemia Hypomagnesemia Significant bradycardia Bradyarrhythmias Uncompensated heart failure Patients should be switched from IV to PO when they are hemodynamically stable, improving clinically, and able to tolerate PO medications. Total duration (IV plus PO step down) described in previous column Options for oral step down therapy should target isolated pathogen. Options for PO step-down if no pathogen identified on respiratory culture: Amoxicillin/clavulanate 875mg Q12h PLUS/MINUS azithromycin Cefpodoxime 200mg Q12h¹ PLUS/MINUS azithromycin If TypeI IgE-mediated penicillin or any legitimate cephalogen altery is a start of the placement o

.

tion (Cuidalia ſ 41 $\mathbf{\Gamma}_{\mathbf{r}}$ into T. 4 of D • 4

§ Prior to confirmation of pathogen1. Refer to SJMHS antibiotic dosing tables for dose adjustments in renal dysfunction.



Guide	lines for Treatment of Ur	inary Tract Infections ((UTIs) in Adults – January 2018
Infection	Antimicrobial	Duration	Comments
Asymptomatic Bacteriuria	Therapy [§] National guidelines recomm (pregnancy, prior to urologi		mptomatic bacteriuria except in select circumstances
<u>When to order a</u> <u>Urinalysis or Urine</u> <u>Culture</u> Recommendations	 Fever >38° C or rigors w Urgency, frequency, dysu Suprapubic pain or tender Costovertebral pain or ter New onset mental status or 	nria rness nderness	Do not send urine culture if none of these symptoms are present or there is an alternative cause
for when to order a urinalysis or urine culture based on Signs/Symptoms of a I ITI	 alternative cause Acute hematuria Spinal cord injury spastic > 2 SIRS criteria (T > 38 bands) OR shock with co 	ity or autonomic dysreflexia C or < 35 C, HR > 90, RR >2 ncerns for sepsis	antibiotics
	urine culture should not be tr	reated with antibiotics irrespect at organism. <i>Exceptions to this</i>	able to a urinary tract infection, patients with a positive ctive of whether there is pyuria, high bacterial colony <i>s recommendation include pregnant patients and</i> <i>procedure</i> .
Uncomplicated Lower Tract Infections or Cystitis • females without catheters • females without co-morbid conditions listed under complicated UTIs <u>Treatment of Uncomp</u> <u>UTI or Cyst</u> HMS recommendatio	titis n of antibiotic	ole ¹ 3 days 5 days <u>1 dose</u> 3-7 days	 Empiric antibiotic choice should take into consideration recent previous culture results, prior antibiotic use, antibiotic allergies, and severity of presenting illness Fluoroquinolones should be used for only when other oral antibiotic options are not feasible because of their propensity for collateral damage (antibiotic resistance, <i>C.difficile</i> infection, and other adverse effects). When a fluoroquinolone is used for uncomplicated cystitis, the duration of treatment is 3 days. <u>Nitrofurantoin</u> should be avoided in patients with CrCl < 30 mL/min <u>If susceptibility available</u> at 48-72 hrs, deescalate treatment to susceptible narrow-spectrum antibiotic *Fosfomycin is restricted to patients with suspected or confirmed multi-drug resistant organisms. Susceptibilities only established for <i>E. coli</i> and <i>Enterococcus</i> species, but there is data and clinical experience supporting the use of the same susceptibility breakpoints for other members of the <i>Enterobacteriaceae</i> group

§ Prior to confirmation of pathogen

1. Refer to SJMHS antibiotic dosing tables for dose adjustments in renal dysfunction.

References

- Gupta K et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update from the IDSA and ESCMID. *Clin Infect Dis.* 2011;52(5):e103-e120.
- Hooton et al. Diagnosis, Prevention, and Treatment of Catheter Associated UTI in Adults: 2009 International Clinical Practice Guidelines from the IDSA. Clin Infect Dis. 2010;50:625-663.
- Nicolle LE et al. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. *Clin Infect Dis.* 2005;40:643-54.



A Member of Trinity Health Complicated Lower Tract Infections or Cystitis	Includes patients with catheter associated-urinary tract infection for uncomplicated lower UTI/cystitis: Male, urinary catheter p instrumentation, anatomic abnormality or obstruction, signific	resent or removal within the last 48 hrs., GU
Treatment of Complicated Lower UTI without sepsis/bacteremia HMS recommendation of antibiotic treatment and duration	 Nephrolithiasis Urolologic surgery Urinary obstruction Urinary retention Spinal cord injury Asplenia Receiving chemotherapy for a malignancy or malignancy not in remission Moderate/seve re liver disease Hemiplegia CHF Cardiomyopathy Moderate/severe CKD or on HD 	 Sickle cell disease Chronic anti-coagulation Bedridden or using a wheelchair Diabetes mellitus with Hgb A1C>8% Immunodeficiency or immunosuppressive treatments Structural lung disease (moderate-severe COPD, bronchiectasis, home oxygen)
	Trimethoprim-Sulfamethoxazole17 daysPO7 daysNitrofurantoin7 daysFosfomycin1*Q 48 h X 3 dosesCephalexin17 daysIV Ceftriaxone OR IV β -lactam ≤ 7 daysfollowed by other oral agent ≤ 7 days	 Empiric antibiotic choice should take into consideration recent previous culture results, prior antibiotic use, antibiotic allergies, and severity of presenting illness Final choice depends upon confirmation of specific pathogen, the susceptibility pattern, and patient allergies <u>Nitrofurantoin</u> should be avoided in patients with CrCl < 30 mL/min A 3-dose fosfomycin treatment course can be used for women ≤65 years who develop a CA-UTI without upper tract symptoms after the indwelling catheter has been removed Fluoroquinolones should be used for only when other oral antibiotic options are not feasible because of their propensity for collateral damage (antibiotic resistance, <i>C.difficile</i> infection, and other adverse effects). When a fluoroquinolone is used for complicated lower UTIs, the duration of treatment is 7 days.
	Treatment of Uncomplicated Pyelonephritis HMS recommendation of antibiotic treatment and duration	• *Fosfomycin is restricted to patients with suspected or confirmed multi-drug resistant organisms. Susceptibilities only established for <i>E. coli</i> and <i>Enterococcus</i> species, but there is data and clinical experience supporting the use of the same susceptibility breakpoints for other members of the <i>Enterobacteriaceae</i> group
Pyelonephritis and Urinary Tract Infections Associated with	Uncomplicated Pyelonephritis: female pts without catheters of definition for complicated lower UTI Complicated Pyelonephritis: patients with pyelonephritis not n	
Bacteremia § Prior to confirmation of p	Uncomplicated Pyelonephritis Trimethoprim-Sulfamethoxazole ¹ 7-14 days	Empiric antibiotic choice should take into

1. Refer to SJMHS antibiotic dosing tables for dose adjustments in renal dysfunction.

References

- Gupta K et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update from the IDSA and ESCMID. *Clin Infect Dis.* 2011;52(5):e103-e120.
- Hooton et al. Diagnosis, Prevention, and Treatment of Catheter Associated UTI in Adults: 2009 International Clinical Practice Guidelines from the IDSA. Clin Infect Dis. 2010;50:625-663.
- Nicolle LE et al. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. *Clin Infect Dis.* 2005;40:643-54.

Reviewed/ Approved by: SJMH Antimicrobial Subcommittee: Jan 2018; SJMH P & T Committee /2018; Last updated Jan/2018 Contributors: Curtis Collins, PharmD, Anu Malani, MD

Treatment of Uncomplicated Pyelonephritis HMS recommendation for antibiotic treatment and duration	PO Fluoroquinolones ¹ β-lactams (Ceftriaxone)	5-7 days IV therapy: 7 days IV to PO β- lactam/other susceptible PO agent: 7-14 days (combined IV+PO)	 consideration recent prior antibiotic use, severity of presentin Final antibiotic choi antibiotic susceptibi take into considerati the patient Nitrofurantoin and f
<u>Treatment of</u> <u>Complicated</u> <u>Pyelonephritis and</u> <u>UTI with Bacteremia</u> HMS recommendation for antibiotic treatment and duration	Complicated Pyelonephritis and UTI with Bacteremia Complicated Pyelonephritis \$\beta\$-lactams (Ceftriaxone or cefepime ¹ ; may be followed by oral antibiotic therapy) UTI with Bacteremia** \$\beta\$-lactams (Ceftriaxone or cefepime ¹)	7-14 days 7-14 days Shorter courses of therapy (7-days) with a fluoroquinolone or $IV \beta$ -lactam can be considered in female patients without co- morbid conditions who are bacteremic secondary to pyelonephritis or cystitis/lower UTI who have rapid clinical response	 Introduction and function and function of the pyelonephr infection, or patients Oral β-lactams are a efficacy and higher trimethoprim-sulfan fluoroquinolones. If initial therapy shoul by oral β-lactam (as susceptible) **Due to potential c lines (e.g. DVT, CL fluoroquinolones are placement for IV an pathogen is susceptic contraindications to

consideration recent previous culture results, prior antibiotic use, antibiotic allergies, and severity of presenting illness

- Final antibiotic choice should be based on antibiotic susceptibilities of the pathogen and take into consideration antibiotic allergies of the patient
- Nitrofurantoin and fosfomycin should not be used for pyelonephritis, upper urinary tract infection, or patients with bacteremia
- Oral β -lactams are associated with lower efficacy and higher relapse rates compared to trimethoprim-sulfamethoxazole and fluoroquinolones. If a β -lactam is used then initial therapy should be IV therapy followed by oral β -lactam (assuming uropathogen is susceptible)
- **Due to potential complications from PICC lines (e.g. DVT, CLABSI), oral fluoroquinolones are preferred over PICC line placement for IV antibiotics when the urinary pathogen is susceptible and there are no contraindications to fluoroquinolones.

- § Prior to confirmation of pathogen
- 1. Refer to SJMHS antibiotic dosing tables for dose adjustments in renal dysfunction.
- References
 - Gupta K et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update from the IDSA and ESCMID. *Clin Infect Dis.* 2011;52(5):e103-e120.
 - Hooton et al. Diagnosis, Prevention, and Treatment of Catheter Associated UTI in Adults: 2009 International Clinical Practice Guidelines from the IDSA. Clin Infect Dis. 2010;50:625-663.
 - Nicolle LE et al. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. Clin Infect Dis. 2005;40:643-54.

Reviewed/ Approved by: SJMH Antimicrobial Subcommittee: Jan 2018; SJMH P & T Committee /2018; Last updated Jan/2018 Contributors: Curtis Collins, PharmD, Anu Malani, MD



Guidelines for Treatment of Urinary Tract Infections (UTIs) in Adults Dosing Recommendations

Antibiotic	Dose*		
Trimethoprim-sulfamethoxazole (160 mg/800 mg) ¹	1 DS tablet po BID		
Nitrofurantoin ¹	100 mg po BID		
Fosfomycin	3 g dose (see tables for complicated and uncomplicated lower UTI)		
Amoxicillin-clavulanate ¹	875mg po BID		
	Uncomplicated Cystitis: 500 mg po BID		
Cephalexin ¹	500 mg po BID-QID		
	Uncomplicated Cystitis: 500 mg po BID		
Cefpodoxime ¹	100-200 mg po BID		
	Uncomplicated Cystitis: 100 mg po BID		
Cefazolin ¹	1-2g IV q 8 hr		
Cefuroxime ¹ *	500 mg po BID		
	750 mg-1.5g IV q 8 hr		
	Uncomplicated Cystitis: 250 mg po BID		
Piperacillin-tazobactam ¹	3.375 g IV q 6 hr or 4.5 g IV q 6-8 hr		
Ceftriaxone	1-2 g IV once daily		
Cefepime ¹	1-2 g IV q 8-12 hr		
Levofloxacin ¹	250-750 mg QD		
	Uncomplicated Cystitis: 250 mg po QD		
	Uncomplicated Pyelonephritis:		
	7-day duration: 500 mg po QD		
	5-day duration: 750 mg po QD		
Ciprofloxacin ¹	250-750 mg po BID		
	400 mg IV q12 hr		
	Uncomplicated Cystitis: 250 mg po BID		
	Uncomplicated Pyelonephritis: 500 mg po BID		

* Dose depends on disease state (Uncomplicated UTI, Complicated UTI, Pyelonephritis), severity of presentation (e.g. septic shock, severe sepsis), presence of bacteremia, and susceptibilities of the pathogen

§ Prior to confirmation of pathogen

1. Refer to SJMHS antibiotic dosing tables for dose adjustments in renal dysfunction.


References

- Gupta K et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update from the IDSA and ESCMID. *Clin Infect Dis.* 2011;52(5):e103-e120.
- Hooton et al. Diagnosis, Prevention, and Treatment of Catheter Associated UTI in Adults: 2009 International Clinical Practice Guidelines from the IDSA. Clin Infect Dis. 2010;50:625-663.
- Nicolle LE et al. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. *Clin Infect Dis.* 2005;40:643-54.

Appendix B

MICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS

When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing for asymptomatic bacteriuria, except in select circumstances. Therefore urine cultures should only be obtained on adult inpatients for appropriate reasons. In the absence of signs or symptoms (see below) attributable to a urinary tract infection, patients with a positive urine culture and/or pyuria should not be treated with antibiotics irrespective of high bacterial colony count, or a multi-drug resistant organism. The following is an effective strategy for how and when to order a urinalysis and/or urine culture. NOTE: this does not apply to patients being screened for asymptomatic bacteruria (see subsequent page for recommendations in such patients).



*: With this order, a urine culture will only be performed if a urinalysis result indicates infection. This is a strategy to decrease unnecessary antibiotic treatment in samples indicative of colonization and not infection ⁶

^a SIRS Criteria: Heart rate greater than 90bpm, respiratory rate greater than 20 breaths per minute, temperature less than 36° C, white blood count less than 4,000 cells/mm3, temperature greater than 380 C, white blood count greater than 12,000 cells/mm3.

Clinical Setting	Empiric Therapy	Durati	on	Comments
Asymptomatic	In most circumstances,			
Bacteriuria ¹	asymptomatic bacteriuria			
	should not be treated,	Г		
No symptoms of UTI	regardless of pyuria,		<u>No Antibi</u>	otic Treatment for
(listed below)	bacterial density, or			ASB
	isolation of resistant		Recommend	ation in the
UTI symptoms include	organisms.		absence of s	igns or symptoms
(without alternative				to a urinary tract
explanation):			infection, pa	
- Fever >38°C or rigors			-	
without alternative cause			-	e culture and/or
- Urgency, frequency,			1	d not be treated
dysuria - Suprapubic pain or			with antibiot	tics
tenderness			irrespective	of high bacterial
- Costovertebral pain or				t, or a multi-drug
tenderness			resistant org	_
- New onset mental status			10010000000000	
changes with			*Exceptions to	this recommendation
leukocytosis, hypotension,				nt patients and patients
or >/= 2 SIRS criteria ^a			bacteriuria pric	
- Acute hematuria		Ľ		
- Spasticity or autonomic				
dysreflexia in patients				
with spinal cord injury				
Uncomplicated	Preferred			• Fluoroquinolones are no
Cystitis ³	Nitrofurantoin 100 mg po	Nitrofu	rantoin: 5 days	longer recommended as 1 st -
(Non-pregnant female	BID (contraindicated if			line agents due to high
without obstruction,	CrCl <50 ml/min. Due to			rates of <i>E coli</i> resistance
catheters, flank pain, or	the cost of fosfomycin,			and propensity for
co-morbid conditions	nitrofurantoin is preferred if not contraindicated)			collateral damage
except well-controlled	OR			(resistance, C difficile
diabetes mellitus)	Fosfomycin 3 gm po once	Fosfom	ycin: 1 dose	infection). Use should be
	i osioinyein 5 gin po onee	1 0310111	yem. i dose	reserved when other options are not feasible;
				duration of therapy should
Treatment of	Alternative			be 3 days.
<u>Uncomplicated</u>	Cephalexin* 500 mg po	Cephale	exin: 7 days	
Lower UTI or	BID	r	-	• Extended spectrum beta-
Cystitis	OR	TMP/S	MX: 3 days	lactamase positive cases of uncomplicated cystitis can
	TMP/SMX* 1DS tab po			be treated with
HMS	BID			piperacillin/tazobactam,
recommendation of				ampicillin/sulbactam,
antibiotic treatment				amoxicillin/clavulanate,
and duration	*Adjust dose based on			cefepime, ceftriaxone or
	renal function			aztreonam when
	U			susceptible ⁵

Clinical Setting	Empiric Therapy (<u>should take into</u> <u>account recent</u> <u>previous cultures</u>)	Duration	Comments Itreatment for ASB
Complicated Lower Urinary Tract Infection Without Sepsis or Bacteremia (Male, urinary catheter present or removal within the last 48 hrs, recent GU instrumentation , anatomic abnormality or obstruction, pregnancy or other significant co- morbid conditions such as uncontrolled diabetes or immunosuppression) <u>Treatment of Complicated Lower UTI without</u> sepsis/bacteremia HMS recommendation of antibiotic treatment and duration	Preferred oral regimens: Nitrofurantoin 100 mg po BID (contraindicated if CrCl <50 ml/min) OR Fosfomycin 3 gm po X 3 doses given every 48 hours Alternative oral regimens Cephalexin* 500 mg po QID OR TMP/SMX* 1 DS tab po BID (if susceptibility confirmed) Preferred IV option if patient cannot take PO medications Cefazolin* 1g IV Q8H Alternative IV option in patients with anaphylactic PCN/Cephalosporin allergy Aztreonam* 1g IV q8H	Non-Catheter- associated: Treatment duration depends on patient characteristics and clinical response, 7 days usually appropriate Catheter-associated: Prompt resolution of symptoms: 7 days Delayed response to therapy: 10-14 days Special Populations: Women <65 y/o without upper tract symptoms after catheter removal: 3 days	 Asymptomatic bacteriuria in catheterized patients, even in the presence of pyuria, is NOT an indication for treatment Remove urinary catheter whenever possible Nitrofurantoin and Fosfomycin should be avoided if pyelonephritis is suspected Definitive antimicrobial choice should be adjusted based on urine culture and susceptibility testing
Adjust dose based on renal function	Gram-negative bacteria OR Not responding to PO antibiotics Piperacillin-tazobactam 4.5 gm IV q8h Alternative in patients with anaphylactic PCN/Cephalosporin allergy Aztreonam* 1g IV q8H		

Clinical Setting	Empiric Therapy (<u>should take into</u> <u>account recent</u> previous cultures)	Duration	Comments
Uncomplicated Pyelonephritis³ (healthy non-pregnant female)	Preferred Ceftriaxone 1 gm IV daily followed by step-down to oral TMP/SMX* 1 DS tab po BID if susceptible	TMP/SMX: 14 days	 Urine culture and susceptibility testing should be obtained Step-down to oral therapy
	Alternative in patients with anaphylactic PCN/Cephalosporin allergy Ciprofloxacin* 500 mg po	Ciprofloxacin: 7days	is dependent on the susceptibility of the organism
<u>Treatment of</u> <u>Uncomplicated</u> <u>Pyelonephritis</u>	BID or 400 mg iv BID + Gentamicin 2 mg/kg X 1 dose	Beta-lactams: 14 days	• Fluoroquinolones may cause tendinopathy and tendon rupture especially among patients who are older (>60 yo),
HMS recommendation of antibiotic treament and duration	*Adjust dose based on renal function		 malnourished, and on oral glucocorticoids Fluoroquinolones may lead to potentially fatal
			arrhythmias in patients with QT interval prolongation, electrolyte abnormalities, clinically significant bradycardia, and in patients receiving antiarrhythmic medications

Clinical Setting	Empiric Therapy	Duration	Comme	ents
	(should take into			Treatment of
	account recent			Complicated
	previous cultures)			Pyelonephritis and
Complicated	Community-acquired:	Sepsis w/o		UTI with Bacteremia
Urinary Tract	Ceftriaxone 1 gm IV daily	bacteremia:		
Infection with Sepsis	Critically ill, septic	10-14 days, can step- down to oral therapy		HMS
or Bacteremia,	shock, healthcare- or	when stable		recommendation of
Complicated	hospital-acquired:	(see comment)		antibiotic treatment
Pyelonephritis	Piperacillin/tazobactam*			and duration
	4.5gm IV q 8 hrs	Sepsis with		
	Alternative <u>PCN allergy without</u> <u>anaphylaxis, angioedema,</u> <u>or urticaria</u> Cefepime* 1 gm IV q 8h + Vancomycin ** <u>Anaphylactic</u> <u>PCN/Cephalosporin</u> <u>allergy</u> Vancomycin** + Aztreonam* 2gm IV q8h	bacteremia: 14 days from first negative blood culture with IV antibiotics or oral quinolone if susceptible gram-negative Complicated Pyelonephritis: 14 days		

Last updated 12/15/2015 (revision to Page 1 made 2/22/2018) *Renal Dosing Recommendations:

https://pharmwebsp.med.umich.edu/AC/Antimicrobial%20Use%20Guidelines/Antimicrobial%20Dosing%20 Guidelines/Antimicrobial_dosing_recommendations_4-9-2014.pdf

^a SIRS Criteria: Heart rate greater than 90bpm, respiratory rate greater than 20 breaths per minute, temperature less than 36° C, white blood count less than 4,000 cells/mm3, temperature greater than 380 C, white blood count greater than 12,000 cells/mm3.

¹ Nicolle LE, et al. Infectious Diseases Society of America Guidelines for the Diagnosis and Treatment of Asymptomatic Bacteriuria in Adults. Clin Infect Dis 2005;40:643-654.

² Sousa R, et al. Is Asymptomatic Bacteriuria a Risk Factor for Prosthetic Joint Infection? Clin Infect Dis 2014;59:41-47.

³ Gupta K, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120.

⁴ Hooton TM, et al. Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50:625-663.

⁵ Harris PN, et al. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum βlactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015;15:475-485.

⁶ Gandhi T, et al. Importance of urinary tract infection to antibiotic use among hospitalized patients. Infect Control Hosp Epidemiol 2009;30:193-5.

Appendix C EMPIRIC TREATMENT OF COMMUNITY-ACQUIRED PNA IN NON-ICU PATIENTS

Community-acquired pneumonia is defined as pneumonia acquired outside of hospitals or extended-care facilities.

HMS PREFERRED THERAPY	ALTERNATIVE BUT HMS NON-PREFERRED Preferred for patients with cephalosporin allergy, allergy to both macrolides and doxycycline/tetracycline, or severe penicillin allergy.
Ampicillin-Sulbactam 3gm IV q6h, Ceftriaxone 1gm IV q24h, OR Cefotaxime 1g IV q8h PLUS	
Azithromycin 500mg IV/PO x 1 day, then 250mg q24h x 4 days* OR Clarithromycin 500mg PO BID OR Doxycycline 100mg PO BID	Levofloxacin 750 mg PO/IV Once Daily OR Moxifloxacin 400mg PO/IV Once Daily

*Consider substituting doxycycline for azithromycin in patients with a macrolide allergy or at risk for prolonged QT interval.

ORAL STEP-DOWN THERAPY WHEN NO ETIOLOGIC PATHOGEN IDENTIFIED FOR CAP**

Amoxicillin (1g PO 3 x daily) Amoxicillin/clavulanate (875 mg - 2g PO 2 x daily) Cefpodoxime (200mg PO 2 x daily) Cefdinir (300mg PO 2 x daily) Cefditoren (400mg PO 2 x daily) Cefuroxime (500mg PO 2 x daily)

Azithromycin, Doxycyline, or Clarithromycin (see dosing above)

Alternatives: Levofloxcin or Moxifloxacin in setting of severe PCN allergy

**Suggested dosing only. Please individualize based on renal function or other pertinent clinical factors.

Anaerobic coverage is not routinely warranted in non-critically ill patients with aspiration pneumonia.

For more detail about these guidelines, please see the Treatment of Community-Acquired Pneumonia Guidelines published by HMS.

	DEFINTIONS OF COMPLICATED CAP & UNCOMPLICATED CAP	
COMPLICATED CAP	Patients with structural lung disease (e.g. bronchiectasis, pulmonary fibrosis, interstitial lung disease); moderate/severe COPD (excluding COPD exacerbation without pneumonia); documented pnuemonia withMRSA, MSSA, or pseudomonas (or other non-fermenting gram-negative pneumonia); or those who are immunosuppressed.	
UNCOMPLICATED CAP	Patients who do not meet any of the criteria above.	

	DURATION OF ANTIMICROBIAL THERAPY (INCLUDES IV & ORAL)
COMPLICATED CAP	 <u>7 Days</u> if patient is afebrile for 48 hours and has <i>no more than one</i> sign of clinical instability* by day 7 of treatment (Note: Azithromycin duration should be no more than 5 days) Therapy can be continued for patients who are febrile or clinically unstable* on day 7 of treatment
UNCOMPLICATED CAP	<u>5 Days</u> if the patient is afebrile for 48 hours and has <i>no more than one</i> sign of clinical instability* by day 5 of treatment Therapy can be continued for patients who are febrile or clinically unstable* on day 5 of treatment

**Signs of Clinical Instability:* O2 saturation < 90% or new oxygen requirement, HR > 100 bpm, RR > 24 bpm, SBP <90 mmHg, altered mental status (different than baseline)



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as a part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs, and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.




Appendix D

SHOULD THIS PATIENT BE EVALUATED FOR A URINARY TRACT INFECTION?*

Does the patient have any of the following without alternate explanation?

- 1. Urgency, frequency, dysuria
- 2. Suprapubic pain or tenderness
- 3. Costovertebral pain or tenderness
- 4. New onset mental status changes with leukocytosis (WBC > 10 x 10^{9} /L), or hypotension (SBP < 90mmHg), or \geq 2 SIRS criteria
- 5. Fever $> 38^{\circ}$ C or Rigors
- 6. Acute hematuria
- 7. Increased spasticity or autonomic dysreflexia in a spinal cord injury patient



*Symptom-based screening may not be reliable in the in the setting of renal transplants, urinary diversion, or severe sepsis or septic shock. Use your clinical judgment in this population

** Urine culture alone is appropriate for febrile neutropenia and ASB screening for pregnancy or prior to urologic procedures.





Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as a part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs, and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs, and viewpoints of BCBSM or any of its employees.

EMPIRIC THERAPY BASED ON CLASSIFICATION OF URINARY TRACT INFECTION

Empiric choices should take into account previous cultures.

If urine culture is negative & patient was on antibiotics at the time of culture & patient has symptoms (1-7 on the reverse side), it may be appropriate to treat.

PATIENT CATEGORY	PREFERRED**	ALTERNATIVES	DURATION
ASYMPTOMATIC BACTERIURIA* Defined as having NONE of the symptoms (1-7) listed on reverse side	Treatment indicated during pregnancy and prior to urologic procedures		
UNCOMPLICATED LOWER UTI (CYSTITIS)***	Nitrofurantoin or TMP/SMX	Fosfomycin IV or Oral Beta-Lactam (e.g. Cephalexin or Cefpodoxime)	Nitrofurantoin x 5 days (avoid in CrCl < 30 mL/min) Fosfomycin x 1 dose TMP/SMX x 3 days IV or Oral Beta-Lactam x 3-7 days
COMPLICATED LOWER UTI (CYSTITIS)*** Male, urinary catheter present or within last 48 hours, anatomic abnormality or obstruction, significant co-morbidities	Nitrofurantoin, Fosfomycin, or TMP/SMX, Oral Beta-Lactam or IV Beta-Lactam, <u>Severe PCN or</u> <u>Cephalosporin Allergy:</u> Aztreonam		Nitrofurantoin x 7 days Fosfomycin (q48h) x 3-5 doses TMP/SMX x 7 days Oral Beta-Lactam, IV Beta-Lactam, or Aztreonam x 7 days
UNCOMPLICATED PYELONEPHRITIS	TMP/SMX, Fluoroquinolones, or Beta-Lactams		IV Beta-Lactam Therapy followed by Oral Beta-Lactam or Oral TMP/SMX therapy : 7-14 days IV Beta-Lactam Therapy x 7 days TMP/SMX x 7-14 days Fluoroquinolones x 5-7 days
COMPLICATED PYELONEPHRITIS, UTI WITH BACTEREMIA & SEPSIS	Defer to Individual Institutions		Complicated Pyelonephritis : 7-14 days UTI with Bacteremia : 7-14 days [Shorter courses of therapy (7 days) with a fluoroquinolone or IV beta-lactam can be considered in female patients without co-morbid conditions who are bacteremic secondary to pyelonephritis or cystits/lower UTI and have rapid clinical response to therapy.]
*refer to reverse side for conditions when symptom based screening may not be appropriate			

**preferred therapies should reflect local antibiogram data for *E.coli* >80% susceptible

*** excludes patients with sepsis and bacteremia


Follow culture results and de-escalate therapy based on final results and sensitivities.

FOR EACH ANTIBIOTIC: DOCUMENT INDICATION AND PLANNED DURATION FOR ALL PATIENTS.

For more detail about these guidelines, please see the Guidelines for Treatment of UTIs published by HMS.

Appendix E

SITE EXAMPLE OF EDUCATIONAL COMPUTER SCREENSAVER



Appendix F

CAP ORDER SET EXAMPLE

Community Acquired Pneumonia (Pathway A- Non ICU patient)			
 Duration of therapy is 5 days for patients who defervesce within 72 hours and have no more than 1 sign of CAP instability at the time of antibiotic discontinuation Patients with delayed response should discontinue therapy 48-72 hours after defervesce and have no more than 1 sign of CAP instability at time antibiotic discontinuation 			
CAP clinical signs of instability (if different then patient baseline status)			
 HR ≥ 100 bpm RR ≥ 24 breaths/min SBP ≤ 90 mmHg Arterial O2 sat ≤ 90% or pO2 ≤ 60 mmHg on room air Altered metal status 			
 Preferred Therapy PCN allergy without anaphylaxis, angioedema or urticarial Severe PCN allergy AND/OR cephalosporin allergy (anaphylaxis, angioedema, hives) 			
☑ <u>Preferred Therapy</u>			
Preferred regimen- ampicillin/sulbactam AND azithromycin IV/PO			
□ ampicillin-sulbactam (UNASYN) IV 3 g, Intravenous, EVERY 6 HOURS SCHEDULED			
□ azithromycin (ZITHROMAX) tablet 500 mg, Oral, ONCE			
azithromycin (ZITHROMAX) tablet 250 mg, Oral, ONCE DAILY, starting H+24 Hours for 4 doses			
□ azithromycin (ZITHROMAX) IV 500 mg, Intravenous, ONCE			
□ azithromycin (ZITHROMAX) IV 250 mg, Intravenous, EVERY 24 HOURS, Starting H+24 Hours			
□ doxycycline hyclate (VIBRAMYCIN) capsule- ALTERNATIVE for macrolide allergy 100 mg, Oral, 2 TIMES DAILY			
✓ PCN allergy without anaphylaxis, angioedema, or urticarial			
Ceftriaxone AND azithromycin			
Ceftriaxone (ROCEPHINE) IV 1g, Intravenous, EVERY 24 HOURS			
□ azithromycin (ZITHROMAX) tablet 500 mg, Oral, ONCE			
azithromycin (ZITHROMAX) tablet 250 mg, Oral, ONCE DAILY, starting H+24 Hours for 4 doses			
□ azithromycin (ZITHROMAX) IV 500 mg, Intravenous, ONCE			
azithromycin (ZITHROMAX) IV 250 mg, Intravenous, EVERY 24 HOURS, Starting H+24 Hours			
□ doxycycline hyclate (VIBRAMYCIN) capsule- 100 mg, Oral, 2 TIMES DAILY			
Severe PCN allergy AND/OR cephalosporin allergy (anaphylaxis, angioedema, hives)			
Levofloxacin			
Ievofloxacin (LEVAQUIN) tablet 750 mg, Oral, DAILY			
Ievofloxacin (LEVAQUIN) IV 750 mg, Intravenous, EVERY 24 HOURS			

Appendix G UTI ORDER SET EXAMPLE

GEN ADULT Urinary Tract infection

NOTE FOR UTI: *** Empiric therapy selection should take into account recent previous cultures***

- Asymptomatic bacteriuria: In most circumstances, should not be treated, regardless of pyuria, bacterial density, or isolation of resistant organisms. Treatment is recommended in the following circumstance: pregnancy and prior to urologic procedures.
- **Uncomplicated cystitis:** Non- pregnant female without obstruction, catheters, flank pain, or co-morbid conditions except well-controlled diabetes mellitus.
- **Complicated Lower UTI** <u>WITHOUT</u> **Sepsis or Bacteremia:** Male, urinary catheter present or removal within the last 48 hrs, recent GU instrumentation, anatomic abnormality or obstruction, pregnancy or other significant co-morbid conditions such as uncontrolled diabetes or immunosuppression.

Uncomplicated Cystitis (Single Response)

Nitrofurantoin is contraindicated if CrCl < 50mL/min. Due to the cost of fosfomycin, nitrofurantoin is preferred if not contraindicated. Adjust **cephalexin** and **sulfamethoxazole-trimethoprim** dose based on renal function

PREFERRED: nitrofurantoin (MACROBID) capsule (Do NOT use if CrCl<50) 100 mg, Oral, 2 TIME DAILY for 5 Days

□ PREFERRED: fosfomycin (MONUROL) packet 3 g, Oral, ONCE for 1 Doses, for 1 Doses

ALTERNATIVE: cephalexin (KEFLEX) capsule 500 mg, Oral, EVERY 12 HOURS SCHEDULED for 7 Days

ALTERNATIVE: sulfamethoxazole-trimethoprim DS (BACTIRM DS) tablet 1 tablet, Oral, EVERY 12 HOURS SCHEDULED for 3 Days

Complicated Lower Urinary tract infection without Sepsis or Bacteremia (Single Response)

Treatment duration:

Non-Catheter Associated: depends on patient characteristic and clinical response, 7 days usually appropriate **Catheter Associated:**

-Prompt resolution of symptoms: 7 days

-Delayed response to therapy: 10-14 days

-Women <65 y/o without upper tract symptoms after catheter removal: 3 days

Adjust **cephalexin**, **sulfamethoxazole-trimethoprim**, **cefazolin**, **aztreonam**, and **pipercillin-tazobactam** dose based on renal function

Oral Regimens (Single Response)

PREFERRED: nitrofurantoin (MACROBID) capsule (Do NOT use if CrCl<50) 100 mg, Oral, 2 TIME DAILY for 5 Days
 PREFERRED: fosfomycin (MONUROL) packet 3 g, Oral, ONCE for 1 Doses, for 1 Doses
 ALTERNATIVE: cephalexin (KEFLEX) capsule 500 mg, Oral, EVERY 12 HOURS SCHEDULED for 7 Days
 ALTERNATIVE: (if susceptibility confirmed) sulfamethoxazole-trimethoprim DS (BACTIRM DS) tablet 1 tablet, Oral, EVERY 12 HOURS SCHEDULED for 3 Days

IV options if patients cannot take PO medications (Single Response)

PREFERRED: cefazolin (ANCEF) IV 1 g, Intravenous, EVERY 8 HOURS SCHEDULED
 ALTERNATIVE (In patients with anaphylactic PCN/Cephalosporin allergy): aztreonam (AZCTAM) IV 1 g, Intravenous, EVERY 8 HOURS SCHEDULED

History of resistant Gram-negative bacteria OR Not responding to PO antibiotics (Single Response)

PREFERRED: piperacillin-tazobactam (ZOSYN) IV 4.5 g, Intravenous, EVERY 8 HOURS SCHEDULED
 ALTERNATIVE (In patients with anaphylactic PCN/Cephalosporin allergy): aztreonam (AZCTAM) IV 1 g, Intravenous, EVERY 8 HOURS SCHEDULED

Appendix H



What You Need to Know When You Are Prescribed an Antibiotic

Your healthcare team has prescribed antibiotics for you because they think you may have an infection, or another condition which requires antibiotics. Some infections can be treated with antibiotics, which are powerful medications that kill bacteria and can save lives. Like all medications, antibiotics have side effects and should only be used when necessary. Your doctor thinks the benefits of antibiotics outweigh the potential risks at this time.

What are some questions to ask my doctor about antibiotics?

As a patient or caregiver, it is important to understand your or your loved one's antibiotic treatment. Here are some important questions to ask your healthcare team if you haven't already been told the answers:

- What infection or condition is this antibiotic treating and how do you know I have that infection or condition?
- What side effects might occur from this antibiotic?
- How long will I need to take this antibiotic?
- Is it safe to take this antibiotic with other medications or supplements (e.g., vitamins) that I am taking?
- Are there any special directions I need to know about taking this antibiotic? For example, should I take it with food?
- How will I be monitored to know whether my infection or condition is responding to the antibiotic?

Will I have side effects from my antibiotic?

You might. One of the most common side effects of nearly all antibiotics is diarrhea. Usually this is not severe, but occasionally diarrhea can be caused by

Antimicrobial Stewardship Program

- 1 -

a bacteria called *Clostridium difficile (C. difficile,* often shortened to "*C. diff*"). This occurs because antibiotics destroy some of the normal, helpful bacteria in the gut. This allows the *C. difficile* to take over, and puts patients at high risk for this serious infection.

Another common side effect of antibiotics is an allergic reaction. A rash is most common, but some reactions can be more serious. Not all rashes are allergies, though, so it is important to discuss with your doctor if this occurs. The most serious reactions include hives (itchy red patches with pale swelling on top), lip, tongue or throat swelling, wheezing or difficulty breathing, or vomiting.

When should I call my doctor?

Most diarrhea caused by antibiotics is not infectious and should not cause concern. You should let your healthcare team know **right away** if you **develop watery stool three times or more per day** while taking an antibiotic, because that may be a sign of a *C. difficile* infection. Diarrhea caused by *C. difficile* can be serious and must be treated quickly. The risk of getting *C. difficile* diarrhea is highest during the first month, but it can last for up to three months after you stop taking antibiotics. Let your healthcare team know if you develop diarrhea even after you stop taking an antibiotic.

Call your doctor if you develop a rash or other sign of a reaction while taking an antibiotic.

Call 911 to get help immediately if you:

- develop lip, tongue or throat swelling
- are wheezing or have difficulty breathing

Remember, antibiotics are life-saving drugs and they need to be used properly. It is important to take your antibiotics exactly as prescribed. If you have any questions about your antibiotics, please talk to your healthcare team.

Disclaimer: This document contains information and/or instructional materials developed by Michigan Medicine for the typical patient with your condition. It may include links to online content that was not created by Michigan Medicine and for which Michigan Medicine does not assume responsibility. It does not replace medical advice from your health care provider because your experience may differ from that of the typical patient. Talk to your health care provider if you have any questions about this document, your condition or your treatment plan.

Adapted from CDC. *You've Been Prescribed an Antibiotic Now What?* Access at: <u>https://www.cdc.gov/getsmart/healthcare/pdfs/16_265926_antibioticfactsheet_v7_508-final.pdf</u>

Patient Education by <u>Michigan Medicine</u> is licensed under a <u>Creative Commons</u> <u>Attribution-NonCommercial-ShareAlike 3.0 Unported License</u>. Last Revised 10/2017 Appendix I

D.I.S.Ch.A.R.G.E. Antibiotics: FACTS AND SOLUTIONS



D.I.S.Ch.A.R.G.E. Antibiotics: FACTS AND SOLUTIONS

D.I.S.Ch.A.R.G.E!

How to improve antibiotic prescribing at hospital discharge.

Defaults and order sets

- Consider use of default durations, default transitions from IV to oral, and recommendations within computerized order-entry to improve early transition to appropriate oral therapy (which can then be continued on discharge)
- Make sure default orders and order sets recommend guideline-appropriate antibiotic choice and duration

<u>Incentivize</u>

> Consider incorporating discharge antibiotic metrics into quality or compensation targets

Discharge <u>S</u>ummary

- > Require documentation of total antibiotic duration in discharge summary
 - Consider enforcing this rule by using smart phrases with hard stops for antibiotic duration in the discharge summary
 - E.g.: To treat (disease), Mr(s) X will continue (abx name) for X additional days, for X days total.

<u>Ch</u>ecklist

Use an antibiotic checklist at discharge to evaluate and ensure antibiotic appropriateness

Audit and Feedback

 Audit and provide feedback of discharge prescriptions (e.g., pharmacists or stewardship team, performance review, quality compensation targets)

<u>R</u>eview: Incorporate antibiotic appropriateness into discharge review process using different members of the care team

- For example
 - With pharmacists (when reviewing or filling discharge medications)
 - With bedside nurse (when reviewing discharge medications)
 - During multidisciplinary/discharge rounds

<u>**G**</u>uidelines

- Make sure your institutional guidelines include oral antibiotic recommendations for discharge for common infections (e.g., pneumonia, urinary tract infection)
 - Prioritize non-fluoroquinolone antibiotics in guidelines
 - o Recommend alternatives to fluoroquinolone antibiotics when possible
 - Provide a recommendation for appropriate duration for different disease states (e.g., 5 days for community-acquired pneumonia), making sure that total duration includes effective inpatient therapy

Educate providers on guidelines and discharge recommendations

- > Formal lectures to residents, physicians (e.g., hospitalist, ID, ED), APPs
- Consider using pocket card
- Consider the use of multiple ways to post guidelines (e.g., websites, apps, printed books)

Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association






ANTIBIOTIC TIME-OUT ✓ CHECKLIST

How to use this checklist:


- Review the need for antibiotics on each patient on antibiotics daily. This review allows you to evaluate new information, such as clinical improvement and new culture results, to update your treatment plan. At a minimum, there are two key times to review antibiotic treatment:
 - ✓ 48-72 hours after admission
 - A lot of diagnostic information has likely returned by now and the patient has likely either improved (or deteriorated) on current therapy. It's therefore time to reassess all information
 - ✓ At hospital discharge
 - Patients being discharged are often less sick and recovering, but not completely better. Sometimes they need to continue antibiotics to treat the infection for which they were hospitalized. This is a great time to make sure the rest of their treatment is guidelines appropriate
 - Other useful times include: any transition of care, change in status, or handoff between providers.



Support for HMS is provided by Blue Cross and Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships program. Although Blue Cross Blue Shield of Michigan and HMS work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association



References:

• Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis. 2007; 44:S27-72.

• Uranga A, et al. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. JAMA Intern Med. 2016;176(9):1257-65.



The Farmington Hills Antimicrobial Stewardship Newsletter

_April, 2018

Agency for Healthcare Research and Quality

Asymptomatic Bacteriuria

Diagnosis

- Asymptomatic bacteriuria (ASB) is a positive urine culture in a patient with no signs or symptoms of a urinary tract infection (e.g., dysuria, frequency, urgency, fever, flank pain).
- Asymptomatic bacteriuria (ASB) is common and often assocated with pyuria (urine containing ≥10 white blood cells per high-powered field).

Population	Prevalence of ASB	Prevalence of Pyuria in Persons With ASB
Healthy premenopausal women	< 5%	32%
Women 65-90 years old	6-16%	
Women > 90 years old	22-43%	
Diabetic women	9-27%	70%
People receiving hemodialysis	28%	90%
Female long-term care residents	25-50%	90%
Male long-term care residents	15-35%	90%
Presence of indwelling urinary catheter	100%	50-100%

Treatment

- The majority of patients with ASB and/or asymptomatic pyuria **SHOULD NOT** be treated.
- Studies have demonstrated that treatment of ASB does not prevent urinary tract infections (UTIs), but is associated with adverse events related to antibiotic use and the development of future UTIs that are antibiotic resistant.
- Exceptions
 - Pregnant patients: treatment prevents preterm labor and pyelonephritis.
 - Patients about to undergo a urologic procedure in which mucosal bleeding is expected (not urinary catheter placement): treatment prevents urosepsis.

How can I prevent unnecessary treatment of asymptomatic bacteriuria?

- Do not order urine cultures unless your patient has signs and symptoms of a UTI, including in
 patients undergoing preoperative evaluation or patients with urinary catheters (except in pregnant
 patients or those about to undergo a urologic procedure in which mucosal bleeding is expected).
 Note:
 - Foul-smelling or cloudy urine does not indicate a UTI.
 - Mental status change alone does not indicate a UTI.

4 Opportunities for Antimicrobial Stewardship in Urinary Tract Infections



When It Comes To Urine Testing, Hold It.

Four opportunities for antimicrobial stewardship in urinary tract disease

Only order a UA to assess for a UTI if symptoms are present

- Symptoms of UTI include dysuria, hematuria, urinary urgency, urinary frequency, fever, suprapubic pain/tenderness, costovertebral pain tenderness and mental status changes without other explanations.
- An abnormal UA does not equal a UTI.

Only order a urine culture if symptoms of a UTI are present

- Without UTI symptoms, a urine culture is not a useful test.
- Symptoms of UTI do NOT include: dizziness, falls, cloudy urine, foul smelling urine, isolated nausea and vomiting.
- Overuse of this test can lead to downstream antibiotic use, allergic reactions and Clostridium difficile infection.

Do not start antibiotics for an abnormal UA

- Many patients can have abnormalities (white blood cells, blood, bacteria, etc.).
- Without symptoms of a UTI, antibiotics are not required.

Do not start antibiotics for an abnormal urine culture

- Urine cultures are frequently abnormal, particularly in females and the elderly.
- There are very few indications for treatment of bacteriuria without symptoms; these include an upcoming urologic surgery or if the patient is pregnant.

Antimicrobial Stewardship Contact: Leslie A. Smith, Antimicrobial Stewardship Pharmacist, 248-471-8058 or Leslieanne.smith@Beaumont.org

Beaumont

Appendix L



Uncomplicated CAP

Dear _____

YOU ARE A TOP PERFORMER!

Upon reviewing the following Uncomplicated Community Acquired Pneumonia (CAP) patient, we would like to share the following with you. Your patient with FIN# ______, admitted on ______, was given a total duration of ____ days of antibiotics. According to both our evidenced-based Institutional and the Michigan Hospital Medicine Safety (HMS) guidelines, this patient received an appropriate duration of antibiotic treatment.

If you have any questions, please contact xxxx (nurse abstractor)or xxxx (ID physician champion). We appreciate your ongoing efforts to provide Remarkable Patient Care, every patient, every time.

Sincerely,

Hospital Medicine Safety Quality Improvement Team-Ann Arbor

"This is a confidential professional/peer review and quality improvement document of xxxx"



Prolonged Duration of Antibiotics for Uncomplicated CAP

Dear _____

Upon reviewing the following Uncomplicated Community Acquired Pneumonia (CAP) patient, we would like to share the following with you. Your patient with FIN# ______, admitted on ______, was given a total duration of ____ days of antibiotics. According to both our evidenced-based Institutional and the Michigan Hospital Medicine Safety (HMS) guidelines, this patient should have received only 5 days of antibiotic treatment. Although we value your clinical judgment, over prescribing of antibiotic therapy increases the risk of *Clostridium difficile* infection, antimicrobial resistance, and the development of antibiotic-associated adverse events. If you have any questions, please contact xxx (nurse abstractor) or xxx (ID physician champion) and we will contact you as soon as possible to discuss.

We appreciate your ongoing efforts to provide Remarkable Patient Care, every patient, every time.

Sincerely,

Hospital Medicine Safety Quality Improvement Team-Ann Arbor


"This is a confidential professional/peer review and quality improvement document of xxxxxxx"

Appendix M

URINE CULTURE ORDERING CHECKLIST

Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. Therefore, urine cultures should only be obtained on adult inpatients for appropriate reasons.


The following is an effective strategy for how and when to order a urinalysis and/or urine culture:



**Symptom-based screening is not reliable in the following cases: pregnancy, prior to urologic procedures, patients with complex urinary anatomy (i.e. nephrostomy tubes, urinary tract stents, h/o urinary diversion surgery, or renal transplant), patients admitted to the ICU, or patients with neutropenia. Use your clinical judgment for this population.







jama.2014.303

De-escalation

► Quick Reference Guide for Hospital Pharmacists

This quick reference guide describes the process of antibiotic de-escalation in patients with **positive bacterial cultures**. This guide is not intended for use in patients on empiric antibiotics with negative bacterial cultures. This 6-step process ensures that patients receive the narrowest-spectrum antibiotic to treat the infection.

\bigcirc

What is de-escalation?

As you know, we often prescribe broad-spectrum antibiotics because we don't have the full clinical picture. In many cases, the initial empiric antibiotic is not the best option for treatment of the patient's infection. De-escalation is when we switch to a narrower-spectrum antibiotic to target the causative pathogen(s) identified on culture.

Key Points

Key Point:

for each patient.

The goal of de-escalation is to determine whether a narrower

antibiotic would be more appropriate

Switching to narrower spectrum antibiotics when clinically indicated can prevent adverse reactions and reduce antibiotic resistance.

Intermountain[®]

Healthcare



What is my role in de-escalation?


Every day, review all patients on broad-spectrum antibiotics in your patient care area and identify those with positive cultures. Review these patients using the 6-step process outlined in this guide to determine whether a narrower antibiotic would optimize therapy. If you feel a change in therapy is needed, work with the prescribing provider and recommend an alternate therapy.

This process is designed for patients with positive cultures only!

\mathbf{D}

What is the process?


For every patient on broad-spectrum antibiotics with a positive culture, review the 6-steps to determine whether de-escalation is appropriate.



Step 1: Evaluate the source

Where was the positive culture obtained? Positive cultures in sites considered sterile need to be taken very seriously. For positive cultures taken from non-sterile sites, use your clinical judgment to determine whether the culture represents an infection or colonization (step 2).

Review the type, source, and status of the culture.



Key Point:

- **Sterile sites:** blood, CSF, bone, pleural fluid, synovial fluid, and other deep surgical sites.
- Non-sterile sites: urine, skin, wounds, sputum, etc.

Step 2: Is an infection present

Is an infection present? The positive culture may represent any one of the following:

- Infection: The presence of pathogenic microorganisms that invade a body part or tissue to cause symptomatic disease.
- **Colonizer**: The presence of microorganisms in a non-sterile site that is not causing infection. These are typically commensal organisms belonging to normal flora and harmless to healthy people; sometimes they perform a vital function (e.g., gut bacteria aid in digestion).
- Contaminant: The unintentional or accidental introduction of microorganisms into a culture, either when the culture was obtained or in the microbiology laboratory.

If a colonizer or contaminant is the cause of the positive culture, **discuss the clinical significance with the provider**.

Key Point:

If the culture shows a colonizer or a contaminant is present, suggest that the provider stop or adjust the patient's antimicrobials.

Example colonizer: A superficial wound swab grows coagulasenegative staphylococci and Enterococcus spp. The site is not sterile, and these bacteria can colonize human skin. In the absence of signs and symptoms of infection, this culture likely represents colonization.

Example contaminant: A female patient with a yeast infection provides a midstream urine culture. Yeast from the urine culture would not represent a Candida UTI.

Step 3: Review culture

Is the positive culture complete? Ask yourself:

- Is the culture finalized? Are other cultures pending?
- Are there other organisms on the Gram stain that didn't grow?
- Does the infectious syndrome warrant broader therapy than the culture would suggest? Do you need to cover more than just the positive culture? For example, if the patient has an intra-abdominal abscess and the blood culture grows *E coli*, anaerobic coverage is still required even though the culture didn't grow anaerobes.
- Does the patient have a comorbid infectious syndrome that warrants broader therapy?

Key Point:

If all cultures aren't final, consider waiting on giving the provider a recommendation for de-escalation.

Step 4: Review resistance

What is the organism's susceptibility profile?

Always review the susceptibility profile to determine what antibiotics will be active. If there is an antibiotic you would like to use that isn't listed on the culture, call your microbiology laboratory for more information.

Key Point:

Talk to the microbiology lab or refer to GermWatch on <u>intermountainphysician.org</u> for regional antibiogram information.

Step 5: Review antibiotic

What antibiotic is the patient on? Can we go any narrower?

After you've assessed the culture and susceptibility profile, ask yourself:

- Is there a narrower antibiotic that will better meet the needs of the patient?
- What exactly should I recommend?

Key Point:

When you are ready to make a de-escalation recommendation, be specific (e.g., include patient-specific dosing).

Narrower				Broader
 Penicillin Oxacillin (nafcillin) Dicloxacillin Ampicillin Amoxicillin Cefazolin Cephalexin Nitrofurantoin 	 Doxycycline Trimethoprim/ sulfamethoxazole Cefoxitin Cefuroxime Azithromycin Clindamycin 	 Amoxicillin/ clavulanate Ampicillin/ sulbactam Ceftriaxone 	 Aztreonam Levofloxacin Ciprofloxacin Cefepime Ceftazidime Ertapenem Vancomycin Ceftaroline 	 Imipenem Meropenem Piperacillin/ tazobactam Daptomycin Linezolid



Step 6: Assess the patient

Are there any patient-specific factors we have to consider?

Consider the following patient-specific factors before making your recommendation:

- Convenience (e.g., dosing interval, IV and PO, side effects, etc.)
- Allergies*
- Drug-drug interaction
- IV or oral conversion*
- * Allergies and IV or PO conversions have their own Quick Reference Guides for your reference. These are included in your training, and you can access them here at any time: <u>intermountain.net/qpsafety/Pages/SCORE.aspx</u>.

Key Point:

Individualize your recommendation to the patient.



Optimizing Stewardship in Community Hospitals

1-801-50-SCORE (72673) | score@imail.org

Appendix P

Antibiotic Indications

► Quick Reference Guide for Hospital Pharmacists

This quick reference guide describes the purpose, process, and requirements for including indications in HELP1 for every antimicrobial prescription. All antibiotics, antifungals, and antivirals are in the scope of these procedures; this card focuses on antibiotics.



The goal

To ensure that antibiotics are prescribed correctly. Ask yourself, is this...

- The RIGHT patient Does the patient have an infection or need antibiotics based on an upcoming procedure?
- The RIGHT drug Which antibiotic is most appropriate?
- The RIGHT dose What dose is most appropriate?
- The RIGHT route IV, oral, switch from IV to oral?
- The RIGHT duration 3 days, 7 days, 6 weeks?

What is an antibiotic indication?

- An antibiotic indication is the reason for antibiotic use either an infection being treated or prophylaxis against an infection.
- Every antibiotic needs to come with an indication for use (like radiology and PRN orders need indications).
- Indications should be as specific as possible and they are **NOT symptoms** (like pain).
- The syndrome the antibiotic is treating, not the organism, is needed for an antibiotic indication.
- A list of appropriate indications is located on the Intermountain Antibiotic Stewardship home page: <u>intermountain.net/qpsafety/Pages/SCORE.aspx</u>.

Key Point:

Knowing why the patient is receiving an antibiotic will enable you to assist the prescriber in providing the RIGHT care to the patient.

Intermountain[®]

Healthcare

Good indication examples:

- Surgical prophylaxis
- Cellulitis
- Community acquired pneumonia
- Empiric sepsis

Bad indication examples:

- Cloudy urine
- Fever
- Pain

Why are antibiotic indications important?

Reason 1: It will help you as a pharmacist.

What indications enable you to do:	For example:
Assess the dose based on the indication and the patient's renal function.	Ceftriaxone 1 gram IV daily is appropriate for community-acquired pneumonia, but not for meningitis.
Assess the spectrum of activity for the given indication.	Piperacillin/tazobactam is appropriate for a healthcare-associated pneumonia but is too broad for a urinary tract infection.
Assist with documenting SCIP compliance, and therefore reimbursement.	Levofloxacin for 7 days after a surgical procedure is appropriate if an infection is documented, but is a SCIP failure if an indication for use is not given.

Key Point:

Antibiotic indications help you validate the dose, spectrum, and documentation of antibiotic prescriptions.

Why are antibiotic indications important? (continued)

Reason 2: Including an antibiotic indication in the EMR is an upcoming CMS requirement.

CMS draft requirements¹

1. C.2.a Facility has a multidisciplinary process in place to review antimicrobial utilization, local susceptibility patterns, and antimicrobial agents in the formulary and there is evidence the process is followed.

1. C.2.b Systems are in place to prompt clinicians to use appropriate antimicrobial agents (e.g., computerized physician order entry, comments in microbiology susceptibility reports, notifications from clinical pharmacists, formulary restrictions, evidence-based guidelines and recommendations).

1. C.2.c Antibiotic orders include an indication for use.

1. C.2.d There is a mechanism in place to prompt clinicians to review antibiotic courses of therapy after 72 hours of treatment.

1. C.2.e The facility has a system in place to identify patients currently receiving intravenous antibiotics who might be eligible to receive oral antibiotic treatment.

Key Point:

Knowing why the patient is receiving an antibiotic will meet upcoming CMS requirements.

Reference

 Centers for Medicare & Medicaid Services. Pre-decisional surveyor worksheet: assessing hospital compliance with the condition of participation for Infection Control. Pilot draft. <u>http://www.cms.gov/Medicare/</u> <u>Provider-Enrollment-and-Certification/</u> <u>SurveyCertificationGenInfo/Downloads/Survey-</u> <u>and-Cert-Letter-12-32.pdf</u>. Published May 18, 2012. Accessed November 13, 2013.



Where are antibiotic indications entered?

Every antibiotic order should have:


Patient name

• Antibiotic

- Dose
- Time and date Route
 - Frequency
- Indication
- Duration (optional)

Key Point:

The prescribing provider writes the indication in the order. The pharmacist enters the indication into HELP1 with the antibiotic.



What if there isn't an indication given?

Do not delay filling the order due to lack of indication!

- Contact the provider at a convenient time (don't call after service hours).
- Add a clarification to the paper chart and indication to the electronic order.
- If the provider gives an invalid indication, refer the provider to the Antimicrobial Prescribing Procedure at your facility.





Key Point:

Fill the prescription, even if an indication isn't provided. Work with the prescribing provider to add the indication to the patient record.